The recent FDA approval of the very first CAR-T therapy marks a significant milestone in the field of cell and gene therapy. However, this also hastens the need to streamline cell therapy workflows to make them more cost-effective, scalable, and safe, and to find solutions to replicate clinical success in solid tumors.
Read the interview by Dr. Tamara Laskowski, titled ‘Unlocking the Potential of CAR-T Therapies for Solid Tumors’, in which she describes the progress researchers at MD Anderson Cancer Center are making in developing off-the-shelf immunotherapies for the treatment of solid tumor malignancies and how the Incucyte® Live-Cell Analysis System and iQue® technologies have been integral in advancing their research.
Learn more about Sartorius solutions for CAR-T Discovery & Development at www.sartorius.com/car-t-research.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.